The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
|Videos|September 8, 2017
Long- vs Short-Course Radiation Therapy in Rectal Cancer
Author(s)Chi Lin, MD, PhD
This video reviews some of the pros and cons of long-course and short-course radiation therapy for the neoadjuvant treatment of rectal cancer.
Advertisement
In this video, Chi Lin, MD, PhD, of the University of Nebraska Medical Center, discusses some of the pros and cons of long-course and short-course radiation therapy for the neoadjuvant treatment of rectal cancer.
Lin gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Advertisement
Related to this article
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
Advertisement
Advertisement
Trending on CancerNetwork
1
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
2
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5